Psychiatry 2001; 158:266-269.
190 David AS, Adams C. Depot antipsychotic medication in the treatment of patients with schizophrenia: (1) meta-review; (2) patient and nurse attitudes. Health Technol Assess 2001; 5:1-61.
191 Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179: 290-299.
192 Knapp M, Ilson S, David A. Depot antipsychotic preparations in schizophrenia: the state of the economic evidence. Int Clin Psychopharmacol 2002; 17:135-140.
193 Edgell ET, Andersen SW, Johnstone BM, et al. Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics 2000; 18:567-579.
194Knapp M, Spiesser J, Carita P. The comparative cost-effectiveness of amisulpride and risperidone in schizophrenia care in western and eastern Europe 2002.
195 Kelly DL, Nelson MW, Love RC, et al. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine. Psychiatr Serv 2001; 52:676-678.
196 Kasper S, Jones M, Duchesne I. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study. Int Clin Psychopharmacol 2001; 16:189-196.
197 Russo PA, Smith, MW, Namjoshi, M. Expenditures in schizophrenia: a comparison of olanzapine and risperidone. 2002.
198. Lewis M, McCrone P, Frangou S. Service use and costs of treating schizophrenia with atypical antipsychotics. J Clin Psychiatry 2001; 62:749-756.
199 Weissman EM, Essock SM. Pharmacoeconomics of antipsychotic medications. Expert Review Pharmacoeconomics Outcomes Research 2002; 2:13-21.
200 Riva MA, Tascedda F, Lovati E, Racagni G. Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs. Brain Res Mol Brain Res 1997; 50:136-142.